

**Recent advances in the delivery of hydrogen sulfide via a macromolecular approach**

Journal:	<i>Polymer Chemistry</i>
Manuscript ID	PY-MRV-06-2018-000938.R1
Article Type:	Minireview
Date Submitted by the Author:	01-Aug-2018
Complete List of Authors:	Urquhart, Matthew; Monash University, Monash Institute of Pharmaceutical Sciences Ercole, Francesca; Monash University, Pharmacy and Pharmaceutical Sciences; Monash University, Materials Engineering Whittaker, Michael; University of New South Wales, Monash University (Pharmacy); Monash University Boyd, Ben; Monash University, Monash Institute of Pharmaceutical Sciences Davis, Thomas; Monash University, Monash Institute of Pharmaceutical Sciences Quinn, John; Monash University, Monash Institute of Pharmaceutical Sciences



Journal Name

ARTICLE

## Recent advances in the delivery of hydrogen sulfide via a macromolecular approach

Received 00th January 20xx,  
Accepted 00th January 20xx

Matthew C. Urquhart,<sup>a</sup> Francesca Ercole,<sup>a</sup> Michael R. Whittaker,<sup>a</sup> Ben J. Boyd,<sup>a</sup>  
Thomas P. Davis <sup>\*a, b</sup> and John F. Quinn<sup>\*a</sup>

DOI: 10.1039/x0xx00000x

www.rsc.org/

Engineered macromolecules such as polymer conjugates, micelles, hydrogels and nanofibers continue to attract interest as drug delivery systems due to their potential to improve therapeutic outcomes. One area where engineered macromolecules have considerable potential is in the delivery of endogenous signalling molecules, such as hydrogen sulfide (H<sub>2</sub>S). Until recently the application and investigation of H<sub>2</sub>S was limited to the use of small molecule donors, although the use of macromolecular systems may confer considerable advantages. This mini review provides a brief overview of recent advances in the use of macromolecules as H<sub>2</sub>S donors. In particular, we examine the use of materials that release H<sub>2</sub>S both spontaneously and in response to chemical or physical triggers. In many of the highlighted examples macromolecules are reported to provide precise, controlled and sustained production of H<sub>2</sub>S, demonstrating their potential as advanced platforms for H<sub>2</sub>S delivery.

### Introduction

Hydrogen sulfide (H<sub>2</sub>S) is an important signalling molecule that elicits effects across a wide range of biological pathways. Abe and Kimura first identified the importance of H<sub>2</sub>S as a biological signalling molecule in the nervous system in 1996,<sup>1</sup> with most studies prior to this focusing on its toxic effects<sup>2</sup> and paying little attention to any potential physiological function. The discovery of the role of H<sub>2</sub>S in endogenous signalling pathways has led to it joining carbon monoxide (CO) and nitric oxide (NO) in the family of gaseous signalling molecules collectively referred to as the gasotransmitters. Since the initial report, H<sub>2</sub>S regulation has become the focus of intense research, and H<sub>2</sub>S-mediated signalling has been associated with a wide array of biological events. Moreover, exogenous delivery of H<sub>2</sub>S has been demonstrated to provide anti-inflammatory,<sup>3</sup> cardioprotective,<sup>4</sup> vasorelaxant,<sup>5</sup> neuroprotective<sup>6</sup> and anti-oxidant<sup>7</sup> effects. As such, the exogenous delivery of H<sub>2</sub>S has been investigated for the treatment of a number of pathologies including Alzheimer's disease<sup>8</sup>, Parkinson's disease<sup>9</sup> and diabetes<sup>10</sup>.

In biomedical research, a variety of different H<sub>2</sub>S donors have been applied.<sup>11</sup> Such agents are not only useful research tools to investigate the biological effects of H<sub>2</sub>S in cells and tissues, but also serve as potential therapeutic agents. The

simplest, although arguably most impractical means of H<sub>2</sub>S administration, is via inhalation. However, this approach is complicated by the toxic and malodorous nature of H<sub>2</sub>S, as well as loss of bioactivity due to oxidation. As an alternative, inorganic sulfide salts have been explored, although these release HS<sup>-</sup> and H<sub>2</sub>S immediately upon solvation, leading to an essentially step-change increase in H<sub>2</sub>S concentration. To overcome these limitations, a number of "slow release" small molecule H<sub>2</sub>S donors have been developed such as the Lawesson reagent derivative GYY4137<sup>12</sup> (row 1, Table 1) to more closely mimic controlled endogenous production. Some of these donors exhibit suitable H<sub>2</sub>S release profiles, although many still suffer from the inherent limitations of small molecule drugs including poor water solubility, high clearance rates and toxicity. For comprehensive reviews on small molecule H<sub>2</sub>S donors the reader is referred to previously published works.<sup>11,14</sup>

The use of macromolecular H<sub>2</sub>S donors presents an opportunity to overcome or mitigate some of the challenges associated with small molecule and inorganic donors.<sup>15</sup> For example, conjugation of a hydrophobic small molecule to a hydrophilic polymer is a simple way of overcoming limits in water solubility. Likewise, incorporation of a readily cleared small molecule into macromolecular structures can drastically alter its pharmacokinetics.<sup>16</sup> The application of a macromolecular platform has been aided by the development of advanced polymerisation methods such as reversible addition–fragmentation chain transfer (RAFT) which has led to the synthesis of an array of macromolecules with well-defined structure and properties.<sup>17</sup> From the simplest drug-polymer conjugates, to more complex macromolecular architectures, polymeric platforms have emerged as highly promising

<sup>a</sup> ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia.

<sup>b</sup> Department of Chemistry, University of Warwick, Coventry, ULCV4 7AL, UK  
E-mail: thomas.p.davis@monash.edu, john.f.quinn@monash.edu

† See DOI: 10.1039/x0xx00000x

delivery vehicles for drugs. Furthermore, complex architectures which respond to biological cues such as intracellular thiols, find application as smart drug delivery vehicles.<sup>18</sup> In terms of H<sub>2</sub>S delivery, the ideal macromolecular donor should deliver a precise amount of H<sub>2</sub>S preferably in response to a specific trigger.<sup>14</sup> The donor should also exhibit good pharmacokinetic parameters and degrade into essentially non-toxic products.

Herein, we examine recent progress in the development of H<sub>2</sub>S donating macromolecules, based on known donors as listed in Table 1. We explore donors that undergo non-specific hydrolysis to release H<sub>2</sub>S, such as thiobenzamides and the dithiolethione derivative ADT-OH. We also discuss those triggered by thiols such as S-arylothiooxime (SATO), and trisulfides which offer the advantage of stimulated H<sub>2</sub>S release in areas of high thiol concentration such as the intracellular environment. An example of nucleophile triggered release of an H<sub>2</sub>S precursor from N-thiolcarboxyanhydride is also highlighted. The application of the light and amine triggerable donor, thiobenzaldehyde, is also discussed (not shown in Table 1). Finally, we present examples wherein a non-conjugated small molecule donor is encapsulated in a polymeric matrix. In many of the highlighted examples, conjugation of the H<sub>2</sub>S donor to a macromolecular scaffold reduces toxicity compared to the unconjugated donor, provides a more controlled H<sub>2</sub>S release profile and alters biological activity compared to the corresponding small molecule.

#### Hydrolytically Active Macromolecular Donors

(4-Methoxyphenyl)-3H-1,2-dithiole-3-thione (also known as anethole dithiolethione, ADT) and 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione (ADT-OH) have been applied as donors of H<sub>2</sub>S, belonging to the class of compounds incorporating the 3H-1,2-dithiole-3-thione (DTT) moiety. DTTs themselves are better known in the pharmaceutical arena as cancer chemopreventive agents and, as such, have been the subject of considerable biochemical investigations.<sup>19</sup> Nonetheless, their extremely complex chemistry is not fully understood. In terms of H<sub>2</sub>S donating ability it has been suggested that DTTs are able to do so hydrolytically in buffers such as PBS, whereby the thiocarbonyl is converted to a carbonyl group.<sup>20</sup> Time course analysis of the rate of hydrolysis has shown it to be a slow process, hastened only by temperatures over 100°C.<sup>21</sup> However, the predominant mechanism for the release of H<sub>2</sub>S *in vivo* and *in vitro* is thought to involve reducing enzymes, as has been reported to occur in rat liver homogenate, rat plasma as well as isolated mitochondria from human astrocyte U373 cells.<sup>20,22</sup> The 1,2-dithiole-3-thione moiety itself can also react with thiols in a number of ways suggesting possible interactions with target proteins could be via cysteine residues, as well intracellular thiols such as glutathione.<sup>23</sup>




Figure 1. ADT-PEG conjugate<sup>24</sup>

Table 1: Known H<sub>2</sub>S donors, some of which have been applied as polymer conjugates

H <sub>2</sub> S Donor Moieties	Release Mechanism
<p><b>GY4137</b></p>	Hydrolysis mechanism involving oxidation of donor
<p><b>1,2-Dithiolethiones (DTTs)</b></p> <p>R=OH (ADT-OH), H, CH<sub>3</sub>, halo, NH<sub>2</sub>, OCH<sub>3</sub> or polymer conjugation</p>	Hydrolysis mechanism involving oxidation of thiocarbonyl group is one possibility, although not significant. Reaction with thiol (mechanism unknown).
<p><b>S-Arylothiooximes (SATO)</b></p> <p>R= H, CH<sub>3</sub>, halo, CN, OCH<sub>3</sub> etc. or polymer conjugation</p>	Reaction of thiol with acyl group followed by rapid S→N acyl transfer. Decomposition of products gives rise to H <sub>2</sub> S
<p><b>Arythioamides</b></p> <p>R = H, OH, OCH<sub>3</sub>, halo etc. or polymer conjugation</p>	Hydrolysis mechanism involving oxidation of donor. Reaction with thiol (mechanism unknown)
<p><b>dialkyl trisulfides, dialkyl tetrasulfides and related polysulfide species.</b></p> <p>R<sub>1</sub> and R<sub>2</sub> = various alkyl substitutions (such as in dialkyl trisulfide DATS) or conjugated polymer</p>	Exchange reactions with thiols produce persulfides (R-SSH) which release H <sub>2</sub> S via further reaction with thiols.
<p><b>Acyl-protected perthiol</b></p> <p>R= acyl group, usually phenyl; R' = acyl group or conjugated polymer</p>	Exchange reactions with thiols produces persulfides (R-SSH) which release H <sub>2</sub> S via further reaction with thiols.
<p><b>N-thiocarboxyanhydrides (NTAs)</b></p> <p>R= CH<sub>3</sub> or conjugated polymer</p>	Carbonyl sulfide (COS) released upon ring-opening by a nucleophile. Conversion of COS into H <sub>2</sub> S occurs by rapid enzymatic conversion (via carbonic anhydrase) or via a slow hydrolysis mechanism.
<p><b>N-(benzoylthio)benzamide (NSHD1)</b></p>	Exchange reactions with thiols produces persulfides (R-SSH) which release H <sub>2</sub> S via further reaction with thiols.
<p><b>JK1</b></p>	pH-dependent (acid) intramolecular cyclization promotes H <sub>2</sub> S release.




Figure 2. a. PEG-PADT block copolymer b. PAM-PADT block copolymer.<sup>25,26</sup>

In 2014, Hasegawa and van der Vlies reported the conjugation of ADT-OH to poly(ethylene glycol) (PEG).<sup>24</sup> The conjugated ADT was constructed using a non-cleavable ether bond linking ADT and PEG (Figure 1). This was favoured over an ester bond due to hydrolytic stability of the resulting construct. <sup>1</sup>H NMR and high resolution mass spectrometry were used to confirm successful nucleophilic substitution of PEG mesylate with ADT-OH, affording the desired PEG-ADT. The synthesised donor conjugate was observed to have lower H<sub>2</sub>S generating capacity than its parent compound, ADT-OH. However, encouragingly, the authors also reported PEG-ADT as having a reduced toxicity relative to ADT-OH. This observation was attributed to localisation of PEG-ADT within endosomes compared to the freely diffusing ADT-OH leading to a reduced propensity to react with intracellular proteins. This early study exemplifies the potential utility of using macromolecular H<sub>2</sub>S to offset the toxicity which can be associated with small molecule analogues of the same donor.

In subsequent studies, the same group prepared ADT-functionalised micelles using various methodologies (Figure 2).<sup>25,26</sup> In the first instance, RAFT polymerisation was used to prepare copolymers incorporating hydrophilic polyethylene glycol (PEG) and hydrophobic dithiolethione-bearing (PEG-PADT) segments which formed micelles with an average hydrodynamic diameter of 36 nm, as measured by dynamic light scattering (DLS) (Figure 2a). The authors reported that the donors were stable in cell culture medium and only released H<sub>2</sub>S in the presence of the cell lysate of rat cardiomyocytes, suggesting that reaction with intracellular components was a requirement for H<sub>2</sub>S release. Interestingly, the authors also reported that in contrast to the possibility of cellular damage induced by NF-κB activation by ADT-OH, no such effect was induced by ADT micelles. This highlights the capacity to reduce the cytotoxicity of ADT-OH by incorporation into micellar structures. In the second example, copolymers of hydrophilic poly (*N*-acryloyl morpholine) and hydrophobic dithiolethione-bearing monomer (PAM-PADT) were synthesised (Figure 2b). These copolymers also formed micelles with an average hydrodynamic diameter of 34 nm. The authors reported that these ADT micelles were effective at protecting cells from apoptosis under ischemic conditions at ADT concentrations as low as 0.1 μM, a result attributed to sustained H<sub>2</sub>S release.

Another class of donors which contain a thiocarbonyl group and release H<sub>2</sub>S via an as-yet-unknown mechanism are thiobenzamides (also known as aryl thioamides).<sup>27</sup> The H<sub>2</sub>S

release profiles of a library of small molecule arylthioamides was tested in buffer, using an amperometric sensor, both in the presence and absence of L-cysteine. Interestingly, a majority of the structures tested produced significant, yet sustained levels of H<sub>2</sub>S in the presence of thiol and gave reduced levels in buffer alone. However, this was found to be highly dependent on electronic substitution on the aromatic ring. One of the lead compounds of the study was found to strongly abolish noradrenaline-induced vasoconstriction in isolated rat aortic rings and hyperpolarized the membranes of human vascular smooth muscle cells in a concentration-dependent fashion, an anticipated physiological effect of H<sub>2</sub>S signalling. This was achieved without any added thiols indicating the applicability of these class of compounds as potent H<sub>2</sub>S donors in a biological setting.

In 2015 Ercole *et al.* employed thiobenzamides to produce H<sub>2</sub>S donating macromolecules.<sup>28</sup> In this case the thiobenzamide H<sub>2</sub>S donor groups were introduced via thionation of benzonitrile containing polymeric precursors. A post-polymerisation approach was chosen over directly polymerising thioamide functionalised monomers to avoid potential interference of the thiocarbonyl groups with radical reactions which are essential to the polymerization reaction. Specifically, 3-(4-cyanophenoxy)propyl methacrylate (CPPMA), incorporated into either the hydrophilic or hydrophobic domain of a block copolymer, was subjected to thionation. Incorporation of the H<sub>2</sub>S donor moieties into either the hydrophilic or hydrophobic segments enabled preparation of micelles wherein the H<sub>2</sub>S releasing moiety was resident in either the core or corona (Figure 3). The resulting copolymers were shown to exhibit slow H<sub>2</sub>S release upon hydrolysis and a more rapid release when triggered by cysteine, as measured using an amperometric sensor.




Figure 3 Aryl thioamide-containing block copolymer<sup>28</sup>

Notably, this study also examined the propensity of the macromolecular H<sub>2</sub>S donors to trigger subcellular signalling events. Macromolecular H<sub>2</sub>S donors with the thiobenzamide localised to the micelle corona elicited a slow and sustained increase in cytosolic ERK signalling and a small, fast and sustained increase in plasma membrane-localized PKC activity immediately following addition to HEK293 cells. Studies using a H<sub>2</sub>S-selective fluorescent probe in live cells also confirmed release of H<sub>2</sub>S over physiologically relevant time scales.

Also in 2015, Bowden and co-workers examined the incorporation of thiobenzamide H<sub>2</sub>S donors into macromolecular structures.<sup>29</sup> This was achieved by copolymerising L-lactide with a 4-alkoxythiobenzamide-functionalised lactide derivative. To yield the desired monomer, thiobenzamide was conjugated to lactide by employing a mild reaction of propanedithiol with catalytic I<sub>2</sub>. The copolymerisation was then optimised in CH<sub>2</sub>Cl<sub>2</sub> achieving a 96% conversion with dimethylaminopyridine (DMAP) catalyst. The polymer formed microparticles, although attempts to detect H<sub>2</sub>S liberated from them were unsuccessful. The authors suggested this was due to the low loading and slow release of donor as well as loss of H<sub>2</sub>S either to the atmosphere or via oxidation. It should be noted that no thiol was added during their testing which may account for the low levels of H<sub>2</sub>S released. Nevertheless, this constitutes the first attempt to incorporate H<sub>2</sub>S donor moieties into biocompatible polyesters via ring opening polymerization.




Figure 4. Proposed route of H<sub>2</sub>S generation from SATOs.<sup>31</sup>

### Macromolecular H<sub>2</sub>S Donors triggered by Thiols

In 2014, Foster and Matson reported the first H<sub>2</sub>S-releasing polymer for biological applications which could only be triggered by thiols (*i.e.* no hydrolytic pathway for H<sub>2</sub>S release occurs).<sup>30</sup> These polymers contained S-arylylthiooxime (SATO) functionality which had previously been shown to exhibit H<sub>2</sub>S release upon exposure to the thiol (L-cysteine).<sup>31</sup> The release mechanism is thought to occur by the pathway as shown in Figure 4 as elucidated by analysis of degradation products. Notably, the reversible thiol exchange between the SATO and cysteine gives the arylidene thiooxime along with *N*-benzoylated cysteine via an S- to N-acyl transfer step, similar to native chemical ligation. The subsequent reaction of a second equivalent of cysteine with the thiooxime generates cysteine perthiol, ammonia, and the original aldehyde. The

perthiol intermediate then reacts with another equivalent of cysteine to generate cystine and H<sub>2</sub>S.

To prepare the SATO-functionalised polymers, the authors employed a post-polymerisation modification of pendant aldehyde functionalised polymers which were prepared by RAFT polymerisation. The desired material was generated in three steps (Figure 5). First, the aldehyde containing monomer 2-(4-formylbenzoyloxy)ethyl methacrylate (FBEMA) was copolymerised with 2-(2-methoxyethoxy) ethyl methacrylate (MEO<sub>2</sub>MA). Secondly, the thiocarbonyl-thio end-groups were removed using an excess of AIBN to exclude the possibility of end-group reactions with thiol triggers. Finally, the copolymers were treated with three different S-benzoylthiohydroxylamines (SATHAs) in the presence of catalytic trifluoroacetic acid (TFA) to form the thiooximes. The resulting polymers were shown to undergo thiol-triggered decomposition to release H<sub>2</sub>S by reaction with cysteine and glutathione. Moreover, the kinetics of H<sub>2</sub>S release, as measured with an amperometric microelectrode, were shown to be affected by the electronics of the thiooxime ring, consistent with observations from the initial study on small molecule donors. Specifically, electron-donating groups at the para- position of the SATHA-derived ring were shown to slow the rate of H<sub>2</sub>S release.





Figure 5. Synthesis of S-arylylthiooxime (SATO) functionalised polymers.<sup>30</sup>

In a subsequent study, the same group examined SATO functionalised amphiphilic block copolymer micelles as an advanced H<sub>2</sub>S delivery vehicle to overcome some of the limitations of small linear polymers (*i.e.* clearance).<sup>32</sup> Polymeric micelles in general, especially those with a PEG coating, exhibit prolonged circulation time in blood compared to small molecules.<sup>33</sup> This material was prepared using the same general approach outlined above. However, in this case, FBEMA was polymerised using a PEGylated chain transfer agent to produce a block copolymer, PEG-*b*-poly(FBEMA). The pendant aldehydes in the resulting polymer were then reacted

to yield thiooxime functionalised amphiphilic block copolymers which, due to the hydrophobicity of the SATHA pendants, formed micelles. The kinetics of H<sub>2</sub>S release was measured using a methylene blue assay in which the rate of formation of the blue-coloured dye is monitored spectrophotometrically (UV-Vis) and correlates to the rate of H<sub>2</sub>S release. Upon reaction with thiols, the polymer micelles showed slower and more sustained H<sub>2</sub>S release compared to a related small molecule SATO. A pseudo-first-order kinetic plot of H<sub>2</sub>S release, as generated using a methylene blue assay, gave a 9-fold increase in the half-life of H<sub>2</sub>S release for the micelles compared to the corresponding small molecule (i.e., 3.3 ± 0.4 h vs. 22 minutes for the SATO molecules). The authors attributed this observation to the slower diffusion of thiols into the hydrophobic cores of the polymer micelles.


Very recently, Lu *et al.* reported the first self-fluorescent polymeric H<sub>2</sub>S donor (Figure 6).<sup>34</sup> Similar to the previous study the authors employed a post-polymerisation modification to install a SATO donor group into the macromolecular structure. However, in this example, a salicylaldehyde aggregation induced emission (AIE) fluorophore was also incorporated to facilitate intracellular tracking of the donor. Specifically, RAFT polymerization was used to polymerise well defined poly(3-formyl-4-hydroxybenzyl methacrylate) PFHMA. The salicylaldehyde groups in the synthesised polymer served as handles for the sequential attachment of aminoxy-terminated PEG (PEG-OH), hydrazine and S-benzoylthiohydroxylamine (SBTHA) to introduce water-solubility and biocompatibility, AIE self-fluorescence and H<sub>2</sub>S donating capability, respectively.



**Figure 6.** Synthesis of self-fluorescent S-arylthiooxime (SATO) functionalised polymers.<sup>34</sup>

The resulting polymer formed nanoscale aggregates when dispersed in water, as confirmed by both scanning electron microscopy (SEM) and dynamic light scattering (DLS) (which gave an average hydrodynamic diameter of ~141 nm). The PFHMA-g-PEG/SBTHA conjugate also showed good biocompatibility to L929 cells, which the authors attributed to

the PEG side chains. Upon the addition of a thiol the nanoparticles were reported to disassemble, increasing access of cysteine to the SATO groups, which the authors suggest is responsible for the relatively high release rate observed. Polymer solutions with an equivalent SATO functional group concentration of 100 μM produced a peaking H<sub>2</sub>S concentration value of 80 μM after 55 min in the presence of 1 mM cysteine, as determined using a methylene blue assay. Finally, the authors demonstrated the internalization of the donor polymers by exploiting the AIE behaviour using fluorescence imaging.




**Figure 7.** Synthesis of trisulfide conjugate. i) CHCl<sub>3</sub>, N-methylmorpholine ii) 4-nitrophenyl chloroformate, TEA, CH<sub>2</sub>Cl<sub>2</sub> iii) PEG(2K)-NH<sub>2</sub>, DIPEA, DMAP, CH<sub>2</sub>Cl<sub>2</sub>.<sup>35</sup>

Inspired by the potent H<sub>2</sub>S donor found in garlic, diallyl trisulfide (DATS), Ercole *et al.* developed a PEG-cholesterol conjugate linked by a trisulfide bridge (MeO-PEG-SSS-CHOL, Figure 7).<sup>35</sup> Such trisulfide species are known to produce H<sub>2</sub>S via exchange reactions with thiols (e.g. GSH) via perthiol intermediates.<sup>36</sup> The trisulfide moiety was yielded via the fragmentation reaction of a thiol with methoxycarbonyl 3-(2-hydroxyethyl)trisulfane to form trisulfide-functionalised cholesterol (HO-SSS-CHOL). The final MeO-PEG-SSS-CHOL conjugate was then achieved by coupling PEG-NH<sub>2</sub> with the nitrophenyl carbonate derivative of HO-SSS-CHOL. The trisulfide linkage was shown to be an efficient and degradable H<sub>2</sub>S donor compared to non-H<sub>2</sub>S releasing controls: (i) a disulfide linked PEG-cholesterol conjugate which, although capable of exchanging with thiols, does not release H<sub>2</sub>S; and (ii) a non-cleavable, non-H<sub>2</sub>S releasing conjugate. The hydrophobic and hydrophilic domains in the synthesised material facilitated preparation of both micelles and the first


literature report of H<sub>2</sub>S donating liposomes. Such structures effectively overcome the solubility limitation of DATS which is sparingly soluble in aqueous buffers. These results demonstrate the potential of donor moieties identified from natural sources as inspiration for H<sub>2</sub>S releasing macromolecules. Moreover, the capacity to employ donor moieties as functional linkers that can trigger concomitant disassembly of nanoscale assemblies was also demonstrated for the first time in this work.

Yu *et al.*<sup>37</sup> recently reported the synthesis of polymers with an H<sub>2</sub>S donating, acyl-protected perthiol chain terminus inspired by the small molecule donors of Xian and coworkers.<sup>38</sup> In the initial study, Xian *et al* reported that the corresponding small molecule compound (at an initial concentration of 100 μM), with the same electronic structure as the polymer-conjugated form, produced a H<sub>2</sub>S peaking concentration of ~80 μM at 39 minutes. For the corresponding macromolecular donor, the authors directly modified the thiocarbonylthio end-group formed during RAFT polymerization as a convenient means to incorporate the acyl-protected perthiol moiety. The resulting acyl-protected perthiol end-groups are thought to release H<sub>2</sub>S upon exposure to endogenous thiols via perthiol intermediates as in Figure 8.



**Figure 8.** Production of H<sub>2</sub>S from polymers with acyl-protected perthiol chain termini.

Specifically, the authors first converted the benzodithioate end-group of a RAFT polymer into a pyridyl disulfide, and then reacted with thiobenzoic acid to yield a benzoyl-capped perthiol (Figure 9). This approach was used to modify a series of structures including a homopolymer of (oligoethylene glycol methyl ether) methacrylate (POEGMA), a hydrophilic-hydrophobic block polymer, P[OEGMA]-*b*-[*n*-butyl methacrylate], and a pH-responsive block copolymer, P[OEGMA-*co*-*N,N*-(dimethylamino) ethyl methacrylate]-*b*-[*N,N*-(diisopropylamino)ethyl methacrylate].



**Figure 9.** End-group modification of benzodithioate to acyl protected perthiol.<sup>37</sup>

The H<sub>2</sub>S flux from the donors in the presence of cysteine, as measured using an amperometric sensor, was shown to be dependent on the polymer structure. Consistent with earlier studies the authors reported that H<sub>2</sub>S release from block copolymer micelles was reduced compared to the homopolymer. This was attributed to substantial shielding of the donor end-group in the core of the micelle. The ability to modulate the H<sub>2</sub>S release as a function of pH was demonstrated by using micelles assembled with block copolymer having a pH-responsive poly(*N,N*-(diisopropylamino)ethyl methacrylate) domain. At pH 5 the tertiary amines in the pH-responsive segment become protonated, which promotes micelle disassembly, revealing the end-group and enabling reaction with the trigger (L-cysteine). In contrast, reaction with the trigger is effectively prevented at pH 7.4 where the micelle remains intact. Importantly, the authors also demonstrated that these materials were capable of releasing H<sub>2</sub>S when exposed to endogenous concentrations of thiol in HEK cells, as shown using the fluorescent H<sub>2</sub>S-selective chemosensor SF4.

Matson and co-workers recently developed an alternative macromolecular platform for H<sub>2</sub>S delivery using *N*-thiocarboxyanhydride (NTA) containing polymers capable of releasing carbonyl sulfide (COS), a potential H<sub>2</sub>S precursor.<sup>39</sup> In this case the liberated COS from the NTA moieties was converted to H<sub>2</sub>S by the enzyme carbonic anhydrase (CA). To prepare the materials, a norbornene-NTA monomer was first synthesised and then copolymerised with poly(ethylene glycol) (PEG) functionalised norbornene using ring opening metathesis polymerisation (ROMP), thereby providing a water soluble COS-releasing copolymer. The copolymer was then shown to generate H<sub>2</sub>S in the presence of glycine and CA, as confirmed using both electrochemical sensing and the methylene blue assay. A 3-fold increase in H<sub>2</sub>S release half-life (280 min) was observed when the polymer was employed compared to the corresponding small molecule NTA, as measured by methylene blue assay. Interestingly, while the small molecule NTA was shown to increase proliferation of

brain-derived endothelial cells to a similar extent to sodium sulfide, the copolymer had no impact on proliferation. The authors tentatively attribute this discrepancy to the different release rates associated with the small molecule and copolymer, indicating that the prolonged yet low levels of H<sub>2</sub>S release from macromolecules may not always lead to a favourable outcome when compared to the more rapid release from small molecules. Nonetheless, this report demonstrates an elegant, alternative approach to H<sub>2</sub>S delivery that exploits cellular machinery to convert a released intermediate into the final target molecule.

### Macromolecular H<sub>2</sub>S Donors triggered by light

Xiao *et al.* have recently proposed the use of a multimodal trigger to release H<sub>2</sub>S.<sup>40</sup> In this system H<sub>2</sub>S production was facilitated by first irradiating the material to liberate a reactive intermediate, which then reacted with an amine to liberate H<sub>2</sub>S. Specifically, a stable ( $\beta$ -carbonyl)thioether precursor underwent light-triggered conversion to a thiobenzaldehyde, and the subsequent reaction with an amine formed an imide yielding H<sub>2</sub>S as a by-product (Figure 10).

Interestingly, the authors found the photoactivation to be the rate-determining step compared to the relatively fast imide formation. They also demonstrated the ability to incorporate these donors into water-soluble polymers, hydrogels and polystyrene films by copolymerising a thiobenzaldehyde-containing monomer with appropriate comonomers. Overall this study demonstrated an interesting alternative method for controlled H<sub>2</sub>S delivery based on thioaldehyde chemistry. The non-reliance on a thiol trigger sets this approach apart from many of those previously mentioned. However, the required light irradiation and presence of an amine may itself present challenges for clinical translation of this approach.




Figure 10. Thiobenzaldehyde monomer synthesis and H<sub>2</sub>S release mechanism.<sup>40</sup>

### Polymer-encapsulated H<sub>2</sub>S Donors- Nanofibers

In addition to the direct chemical modification of polymers with H<sub>2</sub>S releasing moieties, it is also possible to physically entrap small molecule donors within a polymer matrix. For example, in 2015, Wang and colleagues fabricated H<sub>2</sub>S donating microfibers and evaluated their potential for application in wound dressings.<sup>41</sup> In this case the authors utilised electrospinning of polycaprolactone (PCL) solutions containing the H<sub>2</sub>S donor *N*-(benzoylthio)benzamide (NSHD1)<sup>42</sup> to create microfibers which release H<sub>2</sub>S when immersed in an aqueous solution containing 1 mM cysteine. The authors employed both energy dispersive X-ray (EDX) and Fourier transform infrared spectrometry (FTIR) to confirm the presence of the H<sub>2</sub>S donor in the fibrous matrix. The H<sub>2</sub>S

release from the fibres was reported to occur over extended timescales, although the overall amount was far less than observed from the NSHD1 donor alone. Furthermore, the microfibers were shown to significantly decrease ROS production in H<sub>2</sub>O<sub>2</sub> treated cells and to promote the expression of wound healing related genes collagen types I and III.

In an extension to this study, the same group employed pH responsive nanofibers<sup>43</sup> using the H<sub>2</sub>S donor JK1<sup>44</sup> (Table 1). This approach benefits from being independent from the intracellular concentration of thiol. In this study, the obtained PCL-JK1 hybrid nanofibers showed pH regulated H<sub>2</sub>S release with lower pH leading to greater and faster release of H<sub>2</sub>S.

### Conclusions and Future Outlook

H<sub>2</sub>S is a critically important molecule in mammalian physiology, and its full catalogue of biological functions is constantly expanding. Given the breadth and depth of these functions, there is a critical need to develop new donors wherein delivery of the molecule can be spatiotemporally controlled. To this end, the development of macromolecular approaches for the controlled and triggered delivery of H<sub>2</sub>S may offer new opportunities for employing this potent yet promiscuous signalling molecule in particular applications. To date, donors with various macromolecular structures have been developed, such as conjugates, micelles, hydrogels and nanofibers. Macromolecular donors offer numerous potential benefits over small molecule donors, such as improved solubility, reduced cytotoxicity, and the potential to readily tune the pharmacokinetics and hence locus of action. As such there is a strong motivation for developing further H<sub>2</sub>S donating macromolecules as potential therapeutics. Moreover, the demonstration that appropriately designed macromolecular H<sub>2</sub>S donors can be incorporated into lipid nanoassemblies offers a further avenue for tailoring the release properties and preparing pharmaceutically relevant H<sub>2</sub>S releasing formulations.<sup>33</sup>

Whilst investigations into the effects of H<sub>2</sub>S-donating compounds on physiological systems continue to multiply, research into the delivery of hydrogen sulfide using a macromolecular approach is only in its infancy as a field. As a result, the focus and nature of such studies remains broad. For example, some research groups have focused on evaluating the differences between small molecule donors vs. conjugated forms whilst others have concentrated on comparing different polymer types and structural forms of the macromolecular donors. Some have focused on comparing release rates while others have investigated cellular toxicity. Undoubtedly, as the field expands it is likely that research will move towards studying the materials in a biological setting to better understand their applicability as therapeutic agents.

Of course, in addition to materials that release H<sub>2</sub>S there is also scope to investigate materials that can potentially sequester H<sub>2</sub>S, and thereby mimic the effect of down-regulating H<sub>2</sub>S producing enzymes. Indeed, there is already some investigation underway in this area.<sup>45</sup>



H<sub>2</sub>S is, together with nitric oxide and carbon monoxide, one of the three so-called gasotransmitters. As such, these molecules provide important precedents as to how the field might evolve in coming years. Given that appreciation of the role of H<sub>2</sub>S in mammalian physiology has expanded in much the same way as it did for nitric oxide, so too we might anticipate the investigation of H<sub>2</sub>S-releasing materials to follow a similar trajectory to that of NO-releasing materials.<sup>46,47</sup> Should that be the case, then the future of research into macromolecular H<sub>2</sub>S donors looks very bright indeed.

### Conflicts of interest

There are no conflicts to declare.

### Acknowledgements

This work was carried out within the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology (CE140100036). T. P. D. is grateful for the award of an Australian Laureate Fellowship from the ARC and J.F.Q. for an ARC Future Fellowship (FT170100144). All authors acknowledge support from Monash University (MIPS) and the Monash-Warwick Alliance.

### Notes and references

- 1 K. Abe and H. Kimura, *J. Neurosci.*, 1996, **16**, 1066.
- 2 R. J. Reiffenstein, W. C. Hulbert and S. H. Roth, *Annu. Rev. Pharmacol. Toxicol.*, 1992, **32**, 109.
- 3 R. C. O. Zanardo, V. Brancalone, E. Distrutti, S. Fiorucci, G. Cirino and J. L. Wallace, *FASEB J.*, 2006, **20**, 2118.
- 4 M. Lavu, S. Bhushan and D. J. Lefer, *Clin. Sci. (Lond.)*, 2011, **120**, 219.
- 5 W. Zhao, J. Zhang, Y. Lu and R. Wang, *EMBO J.*, 2001, **20**, 6008.
- 6 H. Kimura, Y. Nagai, K. Umemura and Y. Kimura, *Antioxid. & Redox Signaling*, 2005, **7**, 795.
- 7 Z.-Z. Xie, Y. Liu and J.-S. Bian, *Oxid. Med. Cell. Longevity*, 2016, **2016**, 1-12.
- 8 K. Eto, T. Asada, K. Arima, T. Makifuchi and H. Kimura, *Biochem. Biophys. Res. Commun.*, 2002, **293**, 1485.
- 9 L. F. Hu, M. Lu, C. X. Tiong, G. S. Dawe, G. Hu and J. S. Bian, *Aging Cell*, 2010, **9**, 135-146.
- 10 C. Szabo, *Antioxid. & Redox Signaling*, 2012, **17**, 68.
- 11 Y. Zhao, T. D. Biggs and M. Xian, *Chem. Commun.*, 2014, **50**, 11788.
- 12 L. Li, M. Salto-Tellez, C.-H. Tan, M. Whiteman and P. K. Moore, *Free Radical Biol. Med.*, 2009, **47**, 103.
- 13 Y. Zheng, B. Yu, L. K. La Cruz, M. Roy Choudhury, A. Anifowose and B. Wang, *Med. Res. Rev.*, 2018, **38**, 57.
- 14 C. R. Powell, K. M. Dillon and J. B. Matson, *Biochem. Pharmacol.*, 2018, **149**, 110-123.
- 15 P. T. Wong and S. K. Choi, *Chem. Rev.*, 2015, **115**, 3388.
- 16 N. Larson and H. Ghandehari, *Chem. Mater.*, 2012, **24**, 840.
- 17 K. Ashok, T. Giovanni, C. F. Omid, W. Ralph and L. Robert, *Nat. Rev. Chem.*, 2017, **1**, 0063.
- 18 J. F. Quinn, M. R. Whittaker and T. P. Davis, *Polymer Chem.*, 2017, **8**, 97.
- 19 Y. S. Zhang and R. Munday, *Mol. Cancer Ther.*, 2008, **7**, 3470.
- 20 M. Lee, V. Tazzari, D. Giustarini, R. Rossi, A. Sparatore, P. Del Soldato, E. McGeer and P. L. McGeer, *J. Biol. Chem.*, 2010, **285**, 17318-17328.
- 21 S. D. Zanatta, B. Jarrott and S. J. Williams, *Aus. J. Chem.*, 2010, **63**, 946.
- 22 L. Li, G. Rossoni, A. Sparatore, L. C. Lee, P. Del Soldato and P. K. Moore, *Free Radic. Biol. Med.*, 2007, **42**, 706.
- 23 C. Jacob, E. Battaglia, T. Burkholz, D. Peng, D. Bagrel and M. Montenarh, *Chem. Res. Toxicol.*, 2012, **25**, 588.
- 24 U. Hasegawa and A. van Der Vlies, *Bioconjugate Chem.*, 2014, **25**, 1290.
- 25 U. Hasegawa and A. J. Van Der Vlies, *MedChemComm.*, 2015, **6**, 273.
- 26 T. Takatani-Nakase, M. Katayama, C. Matsui, K. Hanaoka, A. J. Van Der Vlies, K. Takahashi, I. Nakase and U. Hasegawa, *Mol. BioSyst.*, 2017, **13**, 1705.
- 27 A. Martelli, L. Testai, V. Citi, A. Marino, I. Pugliesi, E. Barresi, G. Nesi, S. Rapposelli, S. Taliani, F. Da Settimo, M. C. Breschi and V. Calderone, *ACS Med. Chem. Lett.*, 2013, **4**, 904.
- 28 F. Ercole, F. M. Mansfeld, M. Kavallaris, M. R. Whittaker, J. F. Quinn, M. L. Halls and T. P. Davis, *Biomacromolecules*, 2016, **17**, 371.
- 29 T. R. Long, A. Wongrakpanich, A.-V. Do, A. K. Salem and N. B. Bowden, *Polymer Chem.*, 2015, **6**, 7188.
- 30 J. Foster and J. Matson, *Macromolecules*, 2014, **47**, 5089-5095.
- 31 J. C. Foster, C. R. Powell, S. C. Radzinski and J. B. Matson, *Org. Lett.*, 2014, **16**, 1558.
- 32 J. C. Foster, S. C. Radzinski, X. Zou, C. V. Finkielstein and J. B. Matson, *Mol. Pharmaceutics*, 2017, **14**, 1300.
- 33 Y. Zhang, Y. Huang and S. Li, *AAPS PharmSciTech*, 2014, **15**, 862-871.
- 34 L. Lin, H. Qin, J. Huang, H. Liang, D. Quan and J. Lu, *Polymer Chem.*, 2018, **9**, 2942.
- 35 F. Ercole, M. R. Whittaker, M. L. Halls, B. J. Boyd, T. P. Davis and J. F. Quinn, *Chem. Commun.*, 2017, **53**, 8030.
- 36 D. Liang, H. Wu, M. W. Wong and D. Huang, *Organic letters*, 2015, **17**, 4196.
- 37 S. H. Yu, F. Ercole, N. A. Veldhuis, M. R. Whittaker, T. P. Davis and J. F. Quinn, *Polym. Chem.*, 2017, **8**, 6362.
- 38 Y. Zhao, S. Bhushan, C. Yang, H. Otsuka, J. D. Stein, A. Pacheco, B. Peng, N. O. Devarie-Baez, H. C. Aguilar, D. J. Lefer and M. Xian, *ACS Chem. Biol.*, 2013, **8**, 1283.
- 39 C. R. Powell, J. C. Foster, B. Okyere, M. H. Theus and J. B. Matson, *J. Am. Chem. Soc.*, 2016, **138**, 13477.
- 40 Z. Xiao, T. Bonnard, A. Shakouri-Motlagh, R. A. L. Wylie, J. Collins, J. White, D. E. Heath, C. E. Hagemeyer and L. A. Connal, *Chem. Euro. J.*, 2017, **23**, 11294.
- 41 S. Feng, Y. Zhao, M. Xian and Q. Wang, *Acta Biomater.*, 2015, **27**, 205.
- 42 Y. Zhao, H. Wang and M. Xian, *J. Am. Chem. Soc.*, 2011, **133**, 15.
- 43 J. Wu, Y. Li, C. He, J. Kang, J. Ye, Z. Xiao, J. Zhu, A. Chen, S. Feng, X. Li, J. Xiao, M. Xian and Q. Wang, *ACS Appl. Mater. Interfaces* 2016, **8**, 27474.
- 44 J. Kang, Z. Li, C. L. Organ, C.-M. Park, C.-T. Yang, A. Pacheco, D. Wang, D. J. Lefer and M. Xian, *J. Am. Chem. Soc.*, 2016, **138**, 6336.
- 45 Q. Yan and W. Sang, *Chem. Sci.*, 2016, **7**, 2100.
- 46 D. A. Riccio and M. H. Schoenfish, *Chem. Soc. Rev.*, 2012, **41**, 3731.
- 47 J. F. Quinn, M. R. Whittaker and T. P. Davis, *J. Control. Release*, 2015, **205**, 190.